Abstract
Background: Infection with HIV-2, a retrovirus that is closely related to HIV-1, is characterized by slower disease progression and transmission, longer latency period and low or undetectable viremia. Host immunity, including production of potent neutralizing antibodies, may be one of the possible contributors to the distinction between the two infections. In an attempt to understand whether HIV-2 infection results in production of neutralizing antibodies and to characterize the nature of the neutralization response we screened plasma of 37 HIV-2 infected individuals for the presence of broadly neutralizing antibodies.Materials and Methods: Thirty seven asymptomatic, ART-naïve, HIV-2 infected individuals were recruited for the study. Plasma obtained from these individuals were screened for the presence of broadly cross reactive neutralizing antibodies (BCNabs) using the standard neutralization screening protocol with a panel of HIV-1 and HIV-2 pseudoviruses. Plasma exhibiting broad neutralization activity were assessed for their potency employing a titration assay. Further, an attempt was made to characterize the neutralization specificity of the plasma exhibiting broad and potent neutralization activity.Result: While majority of the samples tested were capable of neutralizing HIV-2 pseudoviruses with high to moderate potency, one unique sample demonstrated broad cross clade and cross type neutralization with ability to strongly neutralize the vast majority of both HIV-1 and HIV-2 viruses tested (19/20). Preliminary analyses indicate the possible presence of antibodies with multiple glycan epitope binding specificities.Conclusion: The study identified a unique HIV-2 sample with exceptional ability to neutralize HIV-2 viruses and cross-neutralize HIV-1 viruses with great breadth and potency. This sample holds promise for isolation of novel monoclonal antibodies that may exploited as potential therapeutic tools for HIV infection.
Highlights
One of the greatest challenges facing HIV vaccine researchers is the discovery of a vaccine that can induce the production of potent broadly neutralizing antibodies that can act against a large number of contemporaneous viral strains [1]
HIV-2 infection is characterized by slower disease progression and transmissibility, longer latency period, low or undetectable plasmatic viral levels, and slower progression to AIDS than HIV1 [7, 8]
In an attempt to understand the reason behind the better control of HIV-2 infection, we screened the plasma of a cohort of HIV-2 infected individuals for the presence of broadly cross neutralizing antibodies
Summary
One of the greatest challenges facing HIV vaccine researchers is the discovery of a vaccine that can induce the production of potent broadly neutralizing antibodies (bNAbs) that can act against a large number of contemporaneous viral strains [1]. Antibodies that can neutralize diverse viral isolates are reported to be present in about 10–30% of individuals infected with HIV for 2–4 years [2, 3]. The difference in clinical outcomes between the two HIV types offers an opportunity to understand the host immune factors and viral factors responsible for natural control of the virus. In an attempt to understand the reason behind the better control of HIV-2 infection, we screened the plasma of a cohort of HIV-2 infected individuals for the presence of broadly cross neutralizing antibodies. In an attempt to understand whether HIV-2 infection results in production of neutralizing antibodies and to characterize the nature of the neutralization response we screened plasma of 37 HIV-2 infected individuals for the presence of broadly neutralizing antibodies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
